Pharmacoeconomic review report: Rivaroxaban (Xarelto) (Bayer Inc.) indication : in combination with 75 mg to 100 mg acetylsalicylic acid (ASA), for the prevention of stroke, myocardial infarction, and cardiovascular death, and for the prevention of acute limb ischemia and mortality in patients with coronary artery disease (CAD) with or without peripheral artery disease (PAD)
Rivaroxaban is a direct-acting oral anticoagulant that has previously been approved for Canada in doses of 10 mg, 15 mg, and 20 mg for the following indications: prevention of venous thromboembolic events (VTE) in patients who have undergone elective total hip replacement or total knee replacement s...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
CADTH
January 2019, 2019
|
| Edition: | Final (with redactions) |
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Rivaroxaban is a direct-acting oral anticoagulant that has previously been approved for Canada in doses of 10 mg, 15 mg, and 20 mg for the following indications: prevention of venous thromboembolic events (VTE) in patients who have undergone elective total hip replacement or total knee replacement surgery; treatment of VTE (deep vein thrombosis [DVT], pulmonary embolism) and prevention of recurrent DVT and pulmonary embolism; and the prevention of stroke and systemic embolism in patients with atrial fibrillation, for whom anticoagulation is appropriate. The current submission relates to the use of rivaroxaban for patients with coronary artery disease (CAD) with or without peripheral artery disease (PAD) |
|---|---|
| Physical Description: | 1 PDF file (27 pages) illustrations |